Impact of Mogamulizumab in Real-Life Advanced Cutaneous T-Cell Lymphomas: A Multicentric Retrospective Cohort Study

SIMPLE SUMMARY: Mogamulizumab is a recent monoclonal antibody prescribed in the second line to treat advanced mycosis fungoides and Sézary syndromes. We collected data from all patients who used mogamulizumab in six French university hospitals until 1 September 2021. Our primary objective was to det...

Descripción completa

Detalles Bibliográficos
Autores principales: Jouandet, Marie, Nakouri, Inès, Nadin, Lawrence, Kieny, Alice, Samimi, Mahtab, Adamski, Henri, Quéreux, Gaëlle, Chaby, Guillaume, Dompmartin, Anne, L’Orphelin, Jean-Matthieu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996883/
https://www.ncbi.nlm.nih.gov/pubmed/35406431
http://dx.doi.org/10.3390/cancers14071659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996883/
https://www.ncbi.nlm.nih.gov/pubmed/35406431
http://dx.doi.org/10.3390/cancers14071659

Ejemplares similares